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Abstract
Renal angiomyolipoma are part of the PEComa family of neoplasms, and occur both in association with Tuberous Sclerosis
Complex (TSC) and independent of that disorder. Previous studies on the molecular genetic alterations that occur in
angiomyolipoma are very limited. We evaluated 9 angiomyolipoma for which frozen tissue was available from a consecutive
surgical series. Seven of 8 samples subjected to RT-PCR-cDNA sequencing showed mutations in TSC2; none showed
mutations in TSC1 or RHEB. Six of the seven mutations were deletions. We searched for 983 activating and inactivating
mutations in 115 genes, and found none in these tumors. Similarly analysis for genomic regions of loss or gain, assessed by
Affymetrix SNP6.0 analysis, showed no abnormalities. Loss of heterozygosity in the TSC2 region was commonly seen, except
in patients with low frequency TSC2 mutations. We conclude that sporadic renal angiomyolipoma usually have mutations in
TSC2, but not TSC1 or RHEB, and have no other common genomic events, among those we searched for. However,
chromosomal translocations and gene fusion events were not assessed here. TSC2 inactivation by mutation is a consistent
and likely necessary genetic event in the pathogenesis of most angiomyolipoma.
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Introduction
Renal angiomyolipoma (AML) are part of the spectrum of
perivascular epithelioid cell neoplasms (PEComas), which are
defined as ‘‘mesenchymal tumors composed of histologically and
immunohistochemically distinctive perivascular epithelioid cells
(PEC)’’ [1,2]. They have an incidence in the adult population of
about 1 in 1,000 normal individuals [3,4]. Typical AML show
triphasic histology, with tortuous, thick-walled blood vessels,
irregularly arranged sheets and bundles of myoid-appearing
PEC, and lipid-filled PEC that appear to be adipocytes [2].
However, the proportions of these cell types is highly variable, and
cases are seen in which there is predominance of any of myoid
PEC, lipid-filled PEC, or epithelioid PEC. They are seen in
otherwise normal individuals, but occur at much higher frequency
in patients with the genetic disease Tuberous Sclerosis Complex
(TSC), where the incidence in adults is about 70% [5,6]. Renal
AMLs occurring in TSC are often large, multiple, and bilateral in
location, while each of these features is uncommon or rare in non-
TSC individuals who have these neoplasms [4]. Indeed, in a recent
series from a single institution, none of 32 patients with AML who
did not have TSC had bilateral AMLs [7].
Renal AML are often identified as an incidental finding on
abdominal imaging studies done for other reasons. Their chief
clinical significance is that large lesions are prone to spontaneous
hemorrhage, progressive lesions can compromise renal function,
and fat-poor AML are difficult to distinguish from other renal
neoplasms [4]. The management of renal AMLs can be
challenging, and is evolving with the recent recognition that
rapamycin may have benefit for this disease [8]. In addition to
rapamycin and analogues, current management approaches
include selective arterial embolization, radiofrequency ablation,
and nephron-sparing surgery [7,9].
The origin and genetic basis of AMLs is uncertain. AML and
other PEComas express several proteins whose expression is
typical of melanocytes, including GP100silver, the antigen
detected by the HMB-45 monoclonal antibody, suggesting that
the developmental or genetic basis of these neoplasms may be
related to normal or aberrant melanocyte development [10]. This
feature, combined with their smooth muscle cell character, has
suggested that they may have a neural crest origin [11]. AMLs
occurring in TSC are well-known to show evidence of bi-allelic
inactivation of the TSC1 or TSC2 gene, corresponding to the
germline mutation present in such individuals [12].
Limited studies have been performed to analyze the genetic
basis of AML development in non-TSC individuals. Loss of
heterozygosity (LOH) of the TSC2 region has been reported
[13,14], and angiomyolipoma associated with pulmonary lym-
phangioleiomyomatosis have been shown to contain TSC2
mutations in a small number of cases [15]. However, other
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[16]. More recently, LOH for the TSC2 region was identified in
11 of 12 PEComas, and 6 of 14 ‘classic’ angiomyolipoma [17].
Many reports have documented the consistent activation of the
mTOR pathway in these tumors [17,18,19], and reduction or
absence of TSC2 expression was shown in four cases examined by
immunoblotting [19]. Nonetheless, the frequency of TSC1/TSC2
involvement in the development of these tumors has not been
clear, due to the small number of cases examined and
inconsistency of the findings. In addition, no studies have
examined these tumors in any detail for other genetic and
genomic changes that may contribute to their development.
Here we describe detailed genetic analyses as well as the clinical
features of a consecutive series of 9 angiomyolipoma from a single
institution. We find small inactivating mutations in TSC2 in nearly
all tumors, and no evidence for other genetic alterations.
Results
Samples
We studied all AMLs for which frozen tissue was available from
resections performed at a large general hospital (Mass. General
Hosp.) during a 4 year period. Ages and sex of subjects and other
clinical information is shown in Table 1. Nine specimens from 9
patients were available, of whom 1 had a diagnosis of Tuberous
Sclerosis Complex (TSC), and 1 had a diagnosis of Von Hippel
Lindau (VHL) disease. The remaining 7 patients had no clinical
features of TSC other than renal AML, or other known genetic
disease. The tumors all had classic diagnostic features of AML,
though there was a highly variable fat/adipocyte and spindle cell
components, and two had predominant epithelioid morphology
(Table 1, Figure 1). Immunohistochemistry, including staining for
HMB45, was performed when indicated to confirm the diagnosis
(not shown). All AMLs expressed high levels of phospho-S6-S235/
S236 (P-S6), indicative of activation of mTORC1, as we and
others have reported previously [17,18,19] (Figure 1). This finding
is consistent with inactivation of TSC1/TSC2 in these tumors.
Mutational analysis of TSC1, TSC2, and RHEB
Using RNA preparations and RT-PCR, cDNA sequencing was
performed for the entire coding region of TSC1, TSC2, and RHEB.
Seven of eight AML samples sequenced had a total of 5 distinct
deletion and 1 nonsense mutation in TSC2 (Table 2, Figure 2A–
D). All seven were confirmed by analysis of genomic DNA from
the same frozen tumor material, and 6 of 7 were confirmed in
paraffin block extracted DNA preparations from these same
tumors (Table 2). The mutation found in one sample (AML234)
could not be detected in genomic DNA from samples from
paraffin blocks of the same tumor, possibly due to the large size of
that AML (19 cm diameter) and the possibility that it had
occurred by fusion of separate independent AMLs with distinct
molecular lesions. One of the seven AML TSC2 mutations
(AML406) was also seen in normal tissue DNA from the same
patient. This was the patient who had TSC, consistent with it
being the germline TSC2 mutation in that individual. The other
six AML mutations identified in TSC2 were not seen in normal
tissue samples from the corresponding patients, consistent with
their occurrence as somatic events in the AMLs.
TSC2 mutations were not identified by cDNA sequencing in
one AML patient. This patient had a diagnosis of von Hippel
Lindau (VHL) Syndrome, with a germline c.250G.T (p.Val84-
Leu) VHL mutation. Analysis of the AML sample from that VHL
patient indicated that there was equivocal evidence of loss of the
wild type allele of VHL (data not shown). Similarly, there was no
clear evidence of loss of heterozygosity (LOH) findings for markers
within TSC2 (data not shown). This may reflect absence of LOH
in this sample, or alternatively low AML purity.
No mutations were detected in TSC1 or RHEB. RT-PCR of
RHEBL1 failed on all samples, suggesting that its level of
expression was very low to nil in AMLs.
Multiplex ligation-dependent probe assay (MLPA) and LOH
analysis using 3 microsatellite markers was used to assess changes
in copy number in the TSC1 (MLPA only) and TSC2 genes in
these samples. Copy number was normal for all exons of TSC2 in
all samples, while one sample showed evidence for duplication of
TSC1 exon 1. This observation was verified by repeat analysis
using a different set of MLPA probes (data not shown), but the
significance of this finding is uncertain since exon 1 is a non-coding
exon. LOH analyses demonstrated that 5 of 9 samples had
evidence for reduction in allele signal (LOH) for one or more
informative microsatellite markers near TSC2 (data not shown). In
the other four cases, LOH was not seen. However, the
Table 1. Clinical features of patients with AMLs.
Sample Age Sex Size* Location Histology Year
Genetic
diagnosis
AML200 69 F 8.5 cm Surface of R kidney Triphasic 2005
AML227 37 F 8 cm R kidney, extending into
retroperitoneum and mesenteric fat
Spindle cell rich 2006
AML234 47 F 19 cm L extra-renal mass Fat-rich, concurrent renal cell
carcinoma
2006
AML291 44 M 4.5 cm R Kidney Epithelioid 2007
AML400 58 M 3.1 cm R Kidney Triphasic 2008 VHL
AML403 45 M 1.7 cm L Kidney Triphasic 2008
AML406 40 F 15 cm L kidney, extending into retroperitoneum Triphasic 2008 TSC
AML465 47 F 4.9 cm R Kidney Epithelioid 2008
AML490 53 F 2.5 cm L Kidney Triphasic 2009
*largest dimension.
Triphasic denotes classic AML histology, with myoid, adipocyte, and vascular elements.
R, right; L, left.
doi:10.1371/journal.pone.0024919.t001
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those four cases, suggesting significant admixture with normal cells
in those AML specimens, making it difficult or impossible to
discern LOH using microsatellite markers.
Absence of other common cancer mutations or genomic
deletions/amplifications in AMLs
We searched for other mutations (983 total) in a set of 115
common cancer genes by mass spectrometry [20] on five of these
AML samples. No mutations were identified in any gene studied
by this method.
Seven AMLs, for which sufficient quality and quantity of DNA
were available, were analyzed using Affymetrix SNP6.0 arrays to
assess copy number of genomic fragments across the genome, and
search for regions of deletion or amplification. Multiple regions of
potential copy number variation were seen, but the nearly all
aligned with regions known to be variable in copy number in the
human population. Three possible sites of regional, specific
Figure 1. Angiomyolipomas. Gross pictures, micrographs of H&E stains, and immunohistochemical stains with anti-phospho-S6 (S235/S236, P-S6)
of AML200, AML227 and AML234 are shown. AML227 arose in the lower pole of the kidney and extended to the attached colon (arrow). AML234
arose adjacent to the kidney. A small renal cell carcinoma is present in the kidney parenchyma (arrowhead).
doi:10.1371/journal.pone.0024919.g001
Table 2. Summary of genetic findings in AML patients.
Sample
TSC1, TSC2
MLPA
TSC2
LOH
Sequencing
results Onco- map
SNP6.0
Affy
Array
TSC1 TSC2 RHEB
AML200 Neg NO Neg c.5238–5255del
p.(His1746_Arg1751delinsGln)
Neg Neg Negative
AML227 Neg YES Neg c.1210C.T
p.(Gln404X)
Neg Neg ND
AML234 Neg YES Neg c.459delC* Neg Neg ZNF761 amplification
AML291 TSC1-E1 amplif.{ YES ND ND ND Neg ND
AML400 (VHL) Neg NO Neg Neg Neg ND Negative
AML403 Neg YES Neg c.4750delC* Neg ND Negative
AML406 (TSC) Neg YES Neg c.5238–5255del
p.(His1746_Arg1751delinsGln)
Neg Neg SUPT3H deletion
AML465 ND NO Neg c.682–715del34* Neg ND Negative
AML490 ND NO Neg c.4938–4939delGT* Neg ND C7orf10 deletion
*Not previously reported (per LOVD Tuberous sclerosis database for TSC2, chromium.liacs.nl/LOVD2/TSC).
{Amplif. denotes amplification, with three copies detected for exon 1.
ND, not done. Not all studies were performed on all samples due to limitations in amounts of material.
doi:10.1371/journal.pone.0024919.t002
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19, 90 kb) in AML234; deletion of SUPT3H (chr 6, 160 kb) in
AML406; and deletion of C7orf10 (chr 7, 160 kb) in AML490. All
three of these sites were examined by MLPA using duplicate probe
sets for each genomic region, in both AML and normal DNA
samples. The sites of amplification and deletion were confirmed,
respectively, in the AML DNA samples (data not shown).
However, they were also seen to be present in normal kidney
tissue from each patient, suggesting that they were sites of germline
copy number variation, and were not somatic events contributing
to AML development.
Discussion
Similar to past series, there was a small female preponderance in
the cases of angiomyolipoma analyzed here, with 6 of 9 being
female [3]. In addition, seven of the nine cases had no clinical
evidence of genetic disease, reflecting the common clinical
occurrence of this tumor in sporadic form. Further, for 6 of the
7 cases in which a TSC2 mutation was found in the AML, this
mutation was not present in normal tissue DNA, indicating that
they were not germline carriers of a TSC2 mutation. The one
patient in which the TSC2 mutation was present in normal tissue
had TSC, as expected.
We found small mutations in TSC2 in 7 of 8 angiomyolipoma
that were sequenced, and the single case that did not harbor a
mutation was the VHL patient. No mutations were identified in
either TSC1 or RHEB, consistent with previous reports [16].
Interestingly, 6 of 7 mutations in TSC2 were deletions, which is
significantly different from the collective TSC2 mutation database
experience on germline TSC2 mutations [21], for which deletions
account for only 27% of all TSC2 mutations (P=0.013, Chi-
square test). This may reflect differences in mutational mecha-
nisms that occur in somatic vs. germline tissues. Alternatively it
may indicate that deletion mutations have a stronger effect than
missense or other types of mutations in complete elimination of
TSC2 GAP activity toward RHEB. Concordant with these
mutation findings in TSC2, TSC2 LOH was also seen in 5
AMLs; tumor impurity may have contributed to the lack of TSC2
LOH in the other 4 cases. In every case in which TSC2 LOH was
seen, neither MLPA nor the SNP6.0 array indicated copy number
reduction in the region of TSC2, suggesting that copy neutral
LOH had occurred, with loss of one copy of chromosome 16p and
replacement with the other copy including a TSC2 mutation.
Overall, these data indicate that TSC2 inactivation is a consistent
and likely necessary genetic event in the pathogenesis of most
angiomyolipoma.
These observations on the consistent involvement of TSC2 in
the pathogenesis of AML fit with previous observations on the
high frequency of activation of the mTORC1 pathway in this
disease [16,18,19]. The TSC1/TSC2 protein complex is known to
have a critical role in the regulation of the state of activation of
mTORC1, by acting as a GAP (GTPase activating protein) for
Rheb [24,25]. Complete loss of either TSC1 or TSC2 from cells
causes strong activation of mTORC1 with downstream phos-
phorylation effects that are critical for the ensuing growth of these
tumors.
The occurrence of AML in VHL has not been reported
previously. This co-occurrence may be due to chance alone.
However, the lack of a TSC2 point mutation in this single case
suggests the possibility that there is a different molecular
pathogenesis in this circumstance.
Our broader survey for common mutational events gave no
positive findings in AML. None of 983 common cancer point
mutations were identified. In addition, there was no evidence for
genomic deletions or amplifications, that would have been
detected as copy number changes in the SNP analysis. Balanced
translocations and interstitial rearrangements would not be
detected by these methods, and may be present in these tumors.
More detailed genomic studies to investigate this possibility, such
as whole genome sequencing, are appropriate.
Materials and Methods
Angiomyolipoma
Angiomyolipoma tissue samples were obtained at the time of
surgical resection from patients who were operated on at the
Massachusetts General Hospital (MGH) during the period 2005–
2009. This study was approved by the Partners Human Research
Committee, the Institutional Review Board for our hospitals. All
patients were included from whom tumor samples were large
enough to permit collection of frozen tumor. Frozen tissue from
adjacent normal kidney was also available from three patients.
Frozen tissues were stored at 280uC until use. AML samples were
used for both DNA and RNA extraction, by standard methods.
Paraffin cores of AMLs and normal kidney were also used for
extraction of DNA. Paraffin punch cores were chopped into small
pieces with a feather scalpel in tubes, and DNA was extracted
using the QIAamp DNA FFPE Tissue Kit (Qiagen) according to
the manufacturer’s instructions.
RNA analyses
Reverse transcription and PCR (RT–PCR) were performed
using QIAGEN OneStep RT-PCR kit (QIAGEN, Germany) on
RNA isolated from the AML tissues and available normal tissues.
The TSC1 and TSC2 cDNAs were amplified using 6 and 8 pairs of
cDNA primers, respectively, yielding products of size 296–797 nt
(Table S1). Similarly, RHEB and RHEBL1 cDNAs were amplified
using a single primer pair to yield products of size 630 and 656 nt,
respectively. Following PCR amplification of cDNA, fragments
were separated by agarose gel electrophoresis, purified using the
QIAquick Gel Extraction kit (QIAGEN, Germany), and then
sequenced bidirectionally by standard Sanger sequencing with
fluorescent dideoxynucleotides. Mutations identified in this
manner were confirmed by Sanger sequencing of DNA extracted
from the frozen tumors as well as from paraffin-embedded
specimens, including normal control tissue.
Figure 2. Representative sequencing traces demonstrating
TSC2 mutations. A–D. Mutations in TSC2.
doi:10.1371/journal.pone.0024919.g002
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loss of heterozygosity (LOH) analysis with microsatellite
markers
AML DNA samples were examined for genomic deletions in
TSC1 and TSC2 using MLPA including probe sets for each of the
exons of TSC1 and TSC2, as described previously [22]. Three
microsatellite markers in the region of the TSC2 gene were
employed for LOH analyses, and details of the markers,
heterozygosity, genomic location, and primer sequences are given
in Table S2. Genotyping of these markers was performed using
fluorescently tagged oligonucleotides in PCR, followed by capillary
electrophoresis on the ABI 3730. Allele ratios were quantified
using GeneMapper version 3.0 (Applied Biosystems).
Oncomap analysis
We performed mass spectrometry analysis on these samples
(Oncomap), performing 1047 assays interrogating 983 unique
mutations in 115 genes [20]. All positive findings from an initial
multiplex screen were followed up with a more sensitive and
robust singleplex (HME) analysis on the Sequenom MassARRAY
platform (San Diego, CA).
Microarray analysis
AML samples were analyzed for copy number variation using
Affymetrix SNP 6.0 arrays in the Microarray Core facility at Dana
Farber Cancer Institute. Results were compared to that of four
normal DNA samples from unrelated individuals. DNA copy
number data was segmented into regions of estimated equal copy
number using circular binary segmentation (CBS) as implemented
in GenePattern. DNA copy number data as well as segmented
data was visualized in IGV [23] to identify chromosomal regions
of copy number loss and gain, and were compared with known
copy number variable regions identified in previous studies of non-
tumor DNA.
Immunohistochemistry
Tissue sections (5 mm) were prepared from formalin-fixed,
paraffin-embedded renal AML tissue blocks, corresponding to the
frozen AMLs, for immunohistochemical analysis using the avidin-
biotin complex (ABC) method. Briefly, slides were deparaffinized
and sections were heated in a pressure cooker in 10 mM citrate
buffer (pH 6.0) for antigen retrieval. Endogenous peroxidase
activity was blocked by incubation in 3% H2O2 for 20 min at
room temperature. 5% normal goat in Tris-buffered saline-Tween
(TBST) with Avidin was used for blocking. Antibodies to phospho-
S6 (Ser235/236;Cell Signaling Technology #2211; 1:200 dilution)
or Clone HMB-45 (Dako IR052, 1:50 dilution) diluted in 5%
normal goat in TBST with Biotin were applied and incubated
overnight at 4uC. Biotinylated goat anti-rabbit secondary antibody
(Vector Labs; 1:300 dilution) was applied for 30 min prior to
ABC-complex. Negative controls included adjacent sections
incubated in TBST without primary antibody. Immunodetection
was performed with Liquid DAB (DAKO). Hematoxylin was used
as a counterstain, and an adjacent section was stained with
hematoxylin and eosin.
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